GLP-1 weight loss results on TikTok: what the studies actually say

What did @ashleysweightloss2024 actually say?

Nothing about GLP-1 medications. Genuinely, nothing. The entire transcript is a set of song lyrics. Lines like "I'm dancing on the edge of disaster" and "begging please set me free from your eyes" are not weight loss advice. There are zero health claims, no dosing recommendations, no before-and-after framing, and no mentions of semaglutide, tirzepatide, or any medication by name.

The video is categorized under GLP-1 receptor agonists, which suggests the platform or tagging system flagged it for review, but the spoken content is entirely musical. Either the creator filmed themselves lip-syncing or performing to a song, or the transcript capture pulled audio from a background track. Either way, there is no health information to fact-check here. The caption was blank, and no hashtags were provided that would anchor any specific claim.

Does the science back this up?

There is no scientific claim in this video to evaluate. That is not a cop-out. It is the only honest answer. Since the video is categorized in the GLP-1 space, it is worth briefly noting what the actual evidence base looks like for that category, so viewers who arrive here from a GLP-1 search have something useful.

GLP-1 receptor agonists have a substantial clinical record. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4mg produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide at its highest dose produced average weight reductions of up to 20.9%. These are real findings from large, randomized, placebo-controlled trials. They do not make these drugs miracle cures, but the evidence is not thin.

What did they get wrong (or right)?

The creator did not get anything medically wrong, because they did not make any medical statements. That is an unusual outcome for a GLP-1 fact-check, but it is the accurate one. Assigning an error to song lyrics would be its own kind of misinformation.

What is worth flagging is the platform-level concern. A video with 523,200 views landing in the GLP-1 category with no health content at all suggests that algorithmic categorization or viewer behavior is routing people interested in weight loss medications toward content that has no informational value. That is not the creator's fault. But it does mean someone curious about, say, Wegovy side effects or whether compounded semaglutide is safe might watch this and leave no better informed than when they arrived. The information gap in the GLP-1 space is real, and videos like this, however innocently, fill search space without filling knowledge gaps.

What should you actually know?

If you landed on this fact-check because you are researching GLP-1 medications, here is what the evidence actually supports. GLP-1 receptor agonists work by mimicking a gut hormone that slows gastric emptying, reduces appetite, and stimulates insulin secretion in a glucose-dependent way. They are not appetite suppressants in the old stimulant sense. They change hunger signaling at a physiological level.

Common side effects, documented across multiple trials, include nausea, vomiting, constipation, and diarrhea, particularly during dose escalation. The SCALE trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) and STEP programs consistently show these effects are most pronounced in the first several weeks. Serious but rare risks include pancreatitis and a theoretical concern about thyroid C-cell tumors based on rodent data, which the FDA requires be disclosed in labeling. No human trial has confirmed that risk, but it is the reason these drugs carry a boxed warning.

Compounded versions of semaglutide are not the same as FDA-approved brand-name products. FormBlends does not treat them as equivalent, and neither should you based on any TikTok video.